It also suggests that anti-CCP2 is the most powerful of the three autoantibodies to predict arthritis onset, although it should be borne in mind that 50% of ACPA positive risk arthralgia patients did not develop arthritis within 2 years. This evidence concerns the gene AGBL2 and arthritic joint disease.